Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325650 · ClinicalTrials.gov registry record · Phase 3
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,420
- Enrollment target
NCT00325650: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00325650 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 2,420 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (213% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00325650, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,420 participants
- Enrollment target
Study Summary
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline). Secondary objectives: * To assess the effect on weight loss and weight maintenance; sustained effect following a washout period, effect on other markers of glycemic control (fasting glucose, fasting-insulin and HbA1c), glucose tolerance and insulin responses during oral glucose tolerance tests (OGTTs), and on other risk factors (HDL-Cholesterol, TG), * To assess the effect on quality of life * To evaluate long term safety and tolerability.
Interventions
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,420 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Why NCT00325650 stopped before completion
NCT00325650 is an interventional study that assigns participants to a tested intervention. Its 2,420 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (213% higher).
The record links to 0 conditions, and to 2 interventions - of which Rimonabant is the first listed.
NCT00325650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00325650 about?
NCT00325650 is a clinical study titled "Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes". Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline). Secondary objectives: * To assess the effec...
What is the current status of trial NCT00325650?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,420 participants. The study started on 2006-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00325650?
The interventions under investigation include: Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00325650?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00325650's enrollment target sits among peer trials
2,420 89th of 2000 higher than 1,912 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05873387 · 2,420 participants
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
- NCT05345951 · 2,425 participants · NA
Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use
- NCT06676904 · 2,433 participants · NA
Neonatal Platelet Transfusion Threshold Trial
- NCT06128304 · 2,436 participants · NA
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia